Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
Codex DNA (Nasdaq: DNAY) will announce its fourth quarter 2021 financial results on March 22, 2022, after market close. Management will conduct a conference call at 1:30 p.m. PT to discuss results and corporate highlights. The press release and webcast will be accessible via the Investor section of its website. Codex DNA specializes in automated synthetic biology solutions, offering innovative tools like the BioXp™ system, which accelerates DNA and mRNA synthesis, crucial for advancements in precision medicine and therapeutic development.
- Codex DNA's BioXp™ system enables rapid and accurate DNA/RNA synthesis.
- The company holds an industry-standard position with the Gibson Assembly® method.
- None.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 22, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to conference ID 9998693. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Codex DNA’s website for 30 days.
About Codex DNA
Codex DNA is empowering scientists with the ability to create sustainable, synthetic biology solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.
Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com
FAQ
When will Codex DNA release its fourth quarter 2021 financial results?
What time is the Codex DNA conference call for discussing financial results?
How can I access the Codex DNA financial results press release?
What is the significance of the BioXp™ system by Codex DNA?
